Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin,
oxaliplatin (FOLFOX6), bevacizumab, and cetuximab in patients with metastatic colorectal
cancer. FOLFOX6 has proven to be a safe and effective regimen in first line treatment of
advanced colorectal cancer. The role of epidermal growth factor (EGFR) inhibitors in an
earlier treatment setting in combination with optimal chemotherapy regimens is an important
emerging question.